Subsequently, another study revealed a novel CDK8 inhibitor, E966–0530–45,418, that potently inhibited migration of prostate cancer cells and demonstrated anti-metastatic properties in CRPC xenografts [75]. This evidence concerns the gene CDK8 and prostate carcinoma.